Dobutamine
Overview
Dobutamine is a synthetic catecholamine developed in the 1970s as a selective β1-adrenergic receptor agonist. Unlike dopamine, it exhibits minimal effects on α-adrenergic receptors, making it a preferred inotropic agent for short-term treatment of cardiac decompensation. Its primary mechanism involves increasing myocardial contractility without significantly altering heart rate or peripheral vascular resistance. As a pharmaceutical compound, dobutamine is typically administered intravenously in clinical settings. It has become a standard therapy in intensive care units and emergency medicine due to its rapid onset of action (2-10 minutes) and short half-life (approximately 2 minutes). The drug is listed on the WHO Model List of Essential Medicines.
Physical and Chemical Properties
Dobutamine exists as a white crystalline powder with a molecular weight of 301.38 g/mol. Its chemical structure contains a catechol moiety (benzene ring with two adjacent hydroxyl groups) and an amine side chain, characteristic of catecholamine compounds. The substance is stable under recommended storage conditions but degrades upon exposure to light, oxygen, or alkaline solutions. The compound demonstrates good water solubility (50 mg/mL at 25°C), facilitating its formulation as an injectable solution. Its melting point with decomposition at 188-192°C indicates thermal instability, requiring careful handling during pharmaceutical manufacturing. The hydrochloride salt form (CAS 49745-95-1) is commonly used in medical preparations.
Main Applications
In clinical practice, dobutamine serves three principal indications: management of acute decompensated heart failure, treatment of cardiogenic shock, and pharmacological stress testing. For heart failure, it improves cardiac output by 20-50% through positive inotropic effects, typically administered at 2-20 μg/kg/min IV infusion. In stress echocardiography, it mimics exercise-induced cardiac workload to detect coronary artery disease. The pharmaceutical industry produces dobutamine in sterile injectable formulations (commonly 12.5 mg/mL concentrations) for hospital use. Veterinary medicine also employs it for similar cardiac indications in companion animals. Off-label applications include use in pediatric cardiac surgery and septic shock, though evidence remains limited for these uses.
Safety and Storage
Dobutamine requires careful handling due to its cardiovascular potency and chemical instability. Pharmaceutical preparations must be protected from light and stored at controlled room temperature (15-30°C) or refrigerated (2-8°C) for long-term storage. Solutions typically expire within 24 hours after preparation due to oxidative degradation. Healthcare providers must monitor patients for tachycardia, hypertension, and ventricular arrhythmias during administration. Contraindications include idiopathic hypertrophic subaortic stenosis and ventricular tachycardia. The drug is pregnancy category B, meaning animal studies show no risk but human data are insufficient. Proper disposal should follow hazardous pharmaceutical waste protocols.
B2B Procurement Guide
Bulk purchasers of dobutamine should prioritize suppliers with current Good Manufacturing Practice (cGMP) certification and ISO 13485 compliance for pharmaceutical ingredients. Typical commercial quantities range from 100g to 10kg for API (Active Pharmaceutical Ingredient) purchases. Key quality specifications include HPLC purity ≥98%, low heavy metal content (<10 ppm), and sterile filtration for injectable grades. Leading manufacturers include Pfizer, Hospira, and Teva Pharmaceuticals. Buyers should request Certificate of Analysis (CoA), stability data, and regulatory documentation (DMF/ASMF) for international shipments. Current market prices fluctuate based on purity grade and quantity, with contract manufacturing options available for custom formulations. Import/export requires compliance with narcotics control regulations in some jurisdictions.